T1	Participants 58 76	malignant melanoma
T2	Participants 277 339	1984 a multicentre, prospective, randomised, double-blind tria
T3	Participants 411 443	patients with high-risk melanoma
T4	Participants 458 546	the patients had lesions greater than 1.70 mm thick and TNM stage IB or stage II disease
T5	Participants 587 688	coumarin-treated group of 13 patients, and 10 recurrences in the placebo-treated group of 14 patients
#1	AnnotatorNotes T5	13 patients in one group and 14 patients in other group
